Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 13/20 | 1.00 |
| ▸ | CNR2 | P34972 | 9/20 | 1.00 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4053457 | 0.88 | CNR1 (0.79) | CNR1CNR2HTR3ACAPN1CTSB | |
| SCHEMBL4051770 | 0.87 | CNR1 (0.77) | CNR1CNR2HTR3AMEN1KMT2A | |
| SCHEMBL21178272 | 0.85 | CNR1 (0.74) | CNR1CNR2HTR3AKDM4E | |
| SCHEMBL21178271 | 0.85 | CNR1 (0.74) | CNR1CNR2HTR3AKDM4E | |
| SCHEMBL25368841 | 0.84 | CNR1 (0.74) | CNR1CNR2HTR3AKDM4E | |
| SCHEMBL25368839 | 0.84 | CNR1 (0.74) | CNR1CNR2HTR3AKDM4E | |
| SCHEMBL29275142 | 0.81 | CNR1 (1.00) | CNR1CNR2HTR3AKDM4E | |
| SCHEMBL30609587 | 0.81 | CNR1 (1.00) | CNR1CNR2HTR3AKDM4E | |
| SCHEMBL12884556 | 0.81 | CNR1 (0.71) | CNR1CNR2MEN1KMT2A | |
| SCHEMBL25369148 | 0.81 | CNR1 (0.71) | CNR1CNR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4646477-A2 | METHODS AND COMPOSITIONS FOR DISPLAYING PEPTIDE LIBRARIES | Board of Regents, The University of Texas System (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250027072-A1 | METHODS AND COMPOSITIONS RELATED TO ENGINEERED CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-01-23 | — | — | US | disclosed |
| EP-4441203-A1 | METHODS AND COMPOSITIONS RELATED TO ENGINEERED CANNABINOID RECEPTORS | Board of Regents, The University of Texas System (US) | 2024-10-09 | — | — | EP | disclosed |
| WO-2024148130-A2 | METHODS AND COMPOSITIONS FOR DISPLAYING PEPTIDE LIBRARIES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2023102541-A1 | METHODS AND COMPOSITIONS RELATED TO ENGINEERED CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250027072-A1 | METHODS AND COMPOSITIONS RELATED TO ENGINEERED CANNABINOID RECEPTORS | CNR1, CNR2, GPR3 | CNR1 1/4885CNR2 2/4885HTR3A 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.